Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
Authors
Keywords
mTOR inhibitor, Liver cancer, Palliative
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-05-11
DOI
10.1186/s12885-015-1334-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
- (2013) R. K. Kelley et al. ANNALS OF ONCOLOGY
- Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
- (2013) Helen J. Mackay et al. CANCER
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
- (2013) Matthias S. Matter et al. JOURNAL OF HEPATOLOGY
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
- (2013) Sherene Loi et al. PLoS One
- Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma
- (2012) H.-S. Shiah et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma
- (2012) K. V. Menon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma
- (2012) Qian Zhou et al. BIOCHEMICAL PHARMACOLOGY
- Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
- (2012) A.M. Gonzalez-Angulo et al. CANCER TREATMENT REVIEWS
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
- (2012) H. E. Thomas et al. Science Translational Medicine
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas
- (2011) Dakeun Lee et al. MODERN PATHOLOGY
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms
- (2009) E.A. Dunlop et al. CELLULAR SIGNALLING
- Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
- (2009) G. Yu et al. CLINICAL CANCER RESEARCH
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma
- (2009) Hideo A. Baba et al. LIVER INTERNATIONAL
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
- (2008) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started